Arcellx offers financial results and business highlights in the first quarter of 2025

-Imagine-1 data that were accepted for the oral presentation at EHA.

-Imagine-3 study has been updated in order to include the MRD negativity as a double primary endpoint.

-Zwei new board members with commercial and operational expertise-

-The quarter ended the quarter with $ 565 million in cash, which is expected to finance business activities in 2028 —-

Redwood City, California (Business Wire) -Arcellx, Inc. (Nasdaq: ACLX), a biotechnology company that has redesigned cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases today reported in the first quarter on March 31, 2025.

“The provision of therapies that can influence the life of patients is our mission,” said Rami Elghandour, Chairman and Chief Executive Officer from Arcellx. “We are pleased that in addition to progression-free survival, a double primary endpoint for the Immagine 3 protocol was added to a double primary endpoint for the negativity of residual diseases. This supplement corresponds to the feedback of the oncological medicine. Saturday, June 14th, in the European Hematology Association in the European Hematology Association, which dosed in the European Hematology Association. We build on our unique culture and keep the patients at the center of what we do. ”

Recent business progress

• Immagine 1 data that was accepted for the oral presentation at the Congress of the European Hematology Association.
  
  Date: Saturday, June 14, 2025
  
  Time: 17: 00-18: 15 CEST
  
  Session: Treatment of recurrent and/or multiple myeloma
  

• In addition to progression-free survival in global phase 3, the negativity of the minimal residual diseases (MRD) was added as a double primary endpoint as a randomized controlled controlled controlled immagine 3-clinical study. The Immagine 3 study was initiated in the second half of 2024 at around 130 study locations in North America, Europe and in the rest of the world. Anito-Cel works with Kite, a Gilead company.
  

• Appointment of Andrew Galligan and Kristin Myers as Board of Directors.
  

Most recently, Mr. Galligan Chief Financial Officer was at Nevro Corp., a company for medical devices on the market for implantable spinal cords. During his 10-year term in Nevro, he built the financial and company group from the commercial start and drove the sales growth of the year against the previous year. Previously, he was Vice President, Finance and Chief Financial Officer at Ooma, Inc., where he currently acts as a board member. Before that, he worked in the same management capacity at Reliant Technologies, Inc. and helped to create the company by Thermage, Inc., the Executive Experience of Mr. Galligan from Mr. Galligan also includes Senior Financial Leadership functions at Metrika Inc. (acquired by Bayer), Corcept Therapeutics and Amira Medical (from Roche). He has a degree in Business Studies from Trinity College at Dublin University, Dublin, Ireland, and is Fellow of the Irish Institute of Chartered Accountants.

Ms. Myers brings more than 20 years of experience in healthcare, including leadership roles in the areas of payers, providers and Medtech. She is currently Chief Operating Officer at Blue Cross Blue Shield Association that leads strategic, operational and technological teams to support the BCBS system. Previously, Ms. Myers Hopscotch Primary Care founded and led the primary care to serve patient populations in the entire rural America. Previously, Ms. Myers had several positions in Aetna, starting as head of the CEO and chairman, and finally put up with the President of the Great Lakes region. Ms. Myers' career also included time in the investments of risk capital in the healthcare sector and biotech. She has an MBA from Harvard Business School and a BS in Biomedical Engineering from the University of Wisconsin-Madison.

First quarter 2025 financial highlights

Cash, cash equivalent and marketable securities:

As of March 31, 2025, Arcellx had cash, cash equivalent and marketable securities of $ 565.2 million. Arcellx assumes that his cash, cash equivalent and marketable securities will finance their business in 2028.

Income from cooperation:

The turnover of the collaboration was 8.1 million USD and 39.3 million US dollars for the quarters ending on March 31, 2025 and 2024, a decline of USD 31.2 million. This decline was mainly powered by the completion of the dosage and manufacture of Anito-Cel in the Immagine 1 study in the fourth quarter of 2024.

F&E editions:

The research and development costs amounted to $ 50.8 million and USD $ 32.3 million for the quarters ending on March 31, 2025 and 2024 by $ 18.5 million. This increase was mainly due to increased costs in connection with other clinical and preclinical pipeline programs and increased personnel costs, which include non-payment equity remuneration costs.

G&A editions:

The general and administrative expenses amounted to $ 26.2 million and $ 22.7 million for the quarters ending on March 31, 2025 and 2024 by $ 3.5 million. This increase was mainly due to increased personnel costs, which include non -payment stock compensation costs.

Net income or loss:

The net loss was $ 62.3 million and $ 7.2 million for the quarters ending on March 31, 2025 and 2024.

About Arcellx, Inc.

ARCELLX, Inc. is a biotechnology company at clinical level that reinterprets cell therapy by technically constructing innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx is of the opinion that cell therapies are one of the forward columns of medicine, and the mission of Arcellx is to promote humanity by more effective, effective and general accessible. More information about Arcellx can be found at www.arcellx.com. Follow ARCELLX on X @arcellx and LinkedIn.

Predicted statements

This press release contains future -oriented statements within the meaning of Section 27a of the Securities Act of 1933 in the changed version and § 21e of the Securities Exchange Act from 1934 in the changed version. All statements in this press release, which are not purely historical, are future-oriented statements that can be made without restriction: the potential of anito-cool for sensible benefits in patients with several myelomas and to change the treatment paradigm with several myeloma. the potential effects of Anito-Cel on RRMM patients and the expected clinical profile; Toxicity and toxicity trends anito-calel; the potential commercial introduction of Anito-Cel in 2026, subject to FDA approval in cooperation with Kite; The ability of Arcellx to provide cell therapies that meet the most important expectations of patients and clinics and serve the multiple myeloma community; the potential advantages of an additional primary endpoint in the Immagine 3 study; the potential advantages of the additional board members; The expectation that Arcellx 'cash, cash equivalent and marketable securities will finance their business in 2028. and trends regarding the development of Arcellx and organizational growth. The future -oriented statements contained herein are based on the current expectations of Arcellx and contain assumptions that may never prove to be wrong or prove to be wrong. These future-oriented statements are neither promise nor are guarantees and are subject to a variety of risks and uncertainties, including risks, which in the section with the title Part II, point 1a (risk factors) in the quarterly report on 10-QQ quartal for the financial district on March 31, 2025, at the time of time from the time to the time until the time until time until time until the time. The period until the time of time until the time of the time, and the time, and that is subject to the date to the date of time, after the date, and, after the date, and the, and the committee). Sek. These future -oriented statements are made on the date of this press release, and Arcellx assumes no obligation to update or revise future statements, be it based on new information, future events or in any other way, provided that this is required by law.

Arcellx, Inc.
Selected consolidated balance sheet data
(in thousands)
	March 31,		December 31,
	2025		2024
Cash, cash equivalents and marketable securities	$	565.207	$	625.652
Total assets		648.082		711.327
Total liabilities		231.176		256,535
Total capital of shareholders		416.906		454.792

Arcellx, Inc.
Consolidated surgical statements and comprehensive losses
(In thousands, except stock and amounts)
	Three months ended on March 31,
		2025			2024
revenue	$	8.129		$	39.256
Operating costs:
Research and Development		50.801			32.318
General and administrative		26.226			22,748
Total operating costs		77.027			55.066
Loss from operations		(68,898	)))		(15,810	)))
Other income, network		6.628			8.612
Loss of income taxes		(62.270	)))		(7.198	)))
Income tax effort		–			–
Net		(62.270	)))		(7.198	)))
Other comprehensive loss:
Non -realized loss of marketable securities		(199	)))		(1,059	)))
Comprehensive loss	$	(62.469	)))	$	(8.257	)))
Net lust for per share that is due to the regular actions – basic and watering	$	(1.13	)))	$	(0.14	)))
Weighted through regular shares, based on fundamentally and diluted		55.256.464			52.757.973

Contacts

Investor:

Myesha Lacy

ir@arcellx.com
510-418-2412

Media:
Andrea Cohen

Sam Brown LLC

andreocohen@sambrown.com
917-209-7163